Impel Pharmaceuticals
impelpharma.com
Health Care
Neurology & CNS Therapeutics
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Impel Pharmaceuticals liabilities 2022
The liabilities of Impel Pharmaceuticals with headquarters in the United States amounted to U.S.
Read more
Report
Impel Pharmaceuticals Announces Filing of Voluntary Chapter 11 Cases and Signing of "Stalking Horse" Agreement to Facilitate Sale
/PRNewswire/ -- Impel Pharmaceuticals Inc. (OTCQX: IMPL) ("Impel" or "the Company"), a commercial-stage biopharmaceutical company with a mission to develop...
Read more
Report
Safety of INP104 in Migraine Patients With Cardiovascular Risk Factors: Post Hoc Subgroup Analysis of the Phase 3 STOP 301 Study
AHS 2023 STOP 301 CV RiskDownload Presented at the AHS 65th Annual Scientific Meeting, June 15-18, 2023, Austin, Texas Authors: Dafer R, Tietjen G, Rothrock J, Hirman J, Vann R, Gutierrez J, Ray S, Shrewsbury S, Aurora S One sentence summary: This post ho
Read more
Report
Real-World Assessment of Concomitant Medication Use in Patients Using INP104 in the United States
AHS 2023 RWE Concomitant MedicationDownload Presented at the AHS 65th Annual Scientific Meeting, June 15-18, 2023, Austin, Texas Authors: Gill N, Ahmed Z, Vann R, Gutierrez J, Ray S, Aurora S One sentence summary: A longitudinal, retrospective database st
Read more
Report
Real-World Assessment of Baseline Demographic and Clinical Characteristics Among Patients Using INP104 in the United States
AHS 2023 RWE Baseline CharacteristicsDownload Presented at the AHS 65th Annual Scientific Meeting, June 15-18, 2023, Austin, Texas Authors: Gokani T, Nguyen L, Vann R, Gutierrez J, Ray S, Aurora S One sentence summary: A longitudinal, retrospective databa
Read more
Report
Assessment of the Potential for Drug-Drug Interactions Between INP104 and Gepants for Migraine Management Using a Model-based Approach
AHS 2023 DDI and Gepants ENCOREDownload Presented at the AHS 65th Annual Scientific Meeting, June 15-18, 2023, Austin, Texas Authors: Ray S, Torphy B, Joshi S, Vann R, Downing B, Murphy M, Fonseca D, Shrewsbury S, Aurora S One sentence summary: Based on a
Read more
Report
A Cross-Sectional Survey of Prevailing Opinions from Headache Specialists Regarding Status Migrainosus Management
AHS 2023 Status Migrainosus ENCOREDownload Presented at the AHS 65th Annual Scientific Meeting, June 15-18, 2023, Austin, Texas Authors: Robblee J, Vann R, Fitzpatrick C, Murphy M, Downing B, Ray S, Shrewsbury S, Aurora S One sentence summary: Based on a
Read more
Report
Safety of Concomitant Triptan and INP104 Use From the Phase 3 STOP 301 Study in Migraine Patients
AHS 2023 Triptan INP104 Phase3 ENCOREDownload Presented at the AHS 65th Annual Scientific Meeting, June 15-18, 2023, Austin, Texas Authors: Feoktistov A, Vann R, Gutierrez J, Ray S, Shrewsbury S, Aurora S One sentence summary: The safety in migraine patie
Read more
Report
Safety of Concomitant Triptan and INP104 Use From the Phase 3 STOP 301 Study in Migraine Patients
AAN 2023 STOP 301 Triptan UseDownload Presented at the AAN Annual Meeting, April 22-27, 2023 Authors: Alexander Feoktistov, Robert Vann, Judie Gutierrez, Sutapa Ray, Stephen Shrewsbury, Sheena Aurora Objective: To report safety in migraine patients who us
Read more
Report
Assessment of the Potential for Drug-Drug Interactions Between INP104 and Gepants for Migraine Management Using a Model-based Approach
AAN 2023 DDI ENCOREDownload Presented at the AAN Annual Meeting, April 22-27, 2023 Authors: Sutapa Ray, Bradley Torphy, Shivang Joshi, Robert Vann, Brett Downing, Daniella Fonseca, Stephen Shrewsbury, Sheena Aurora Objective: To predict whether coadminist
Read more
Report
Show more news